Search Results Search Sort by RelevanceMost Recent Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 2 Norman C. Fost, MD, MPH Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):300-301. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 3 Gary A. Green, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):301-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 1 Stephen L. Brotherton, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):298-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407. Viewpoint Nov 2005 Steroid Hysteria: Unpacking the Claims Norman Fost, MD, MPH A physician argues in favor of the use of performance-enhancing substances by adult participants in sports. Virtual Mentor. 2005;7(11):767-769. doi: 10.1001/virtualmentor.2005.7.11.oped2-0511. Viewpoint Nov 2005 Medical Ethics and Performance-Enhancing Drugs Carlos R. Hamilton, MD A physician's role in controlling the abuse of performance-enhancing drugs includes educating patients about the harms associated with these drugs and encouraging them to adopt safe and appropriate training programs. Virtual Mentor. 2005;7(11):764-766. doi: 10.1001/virtualmentor.2005.7.11.oped1-0511. Viewpoint Aug 2004 Cosmetic Neurology: For Physicians the Future is Now Anjan Chatterjee, MD Medications for brain enhancement raise many ethical concerns regarding the roles of personal autonomy and responsibility. Virtual Mentor. 2004;6(8):367-371. doi: 10.1001/virtualmentor.2004.6.8.oped1-0408. In the Literature Aug 2004 Ethical Issues in the Application and Prescription of CNS Interventions Abraham P. Schwab, PhD A neuroscientist and a sociologist discuss the ethical concerns with common neurological medicines that are used to enhance or change behavior. Virtual Mentor. 2004;6(8):347-349. doi: 10.1001/virtualmentor.2004.6.8.jdsc1-0408. Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 2 Lucy Godley, MD, PhD Physicians can help oncology patients decide whether to focus on aggressive chemotherapy or less aggressive comfort measures for end-of-life care. Virtual Mentor. 2004;6(11):479-481. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411. In the Literature Nov 2004 Maintaining Integrity in Industry-Sponsored Research Alison Bickford Many ethical and legal issues arise when academic medical research is sponsored by pharmaceutical companies. Virtual Mentor. 2004;6(11):490-493. doi: 10.1001/virtualmentor.2004.6.11.jdsc2-0411. Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 1 David S. Alberts, MD Physicians can help oncology patients decide whether to focus on aggressive chemotherapy or less aggressive comfort measures for end-of-life care. Virtual Mentor. 2004;6(11):477-479. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411. Pagination First page « First Previous page ‹ Previous … Page 12 Page 13 Page 14 Page 15 Page 16 Current page 17 Page 18 Page 19 Page 20 Next page Next › Last page Last »
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 2 Norman C. Fost, MD, MPH Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):300-301. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 3 Gary A. Green, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):301-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
Case and Commentary Jul 2004 Performance-Enhancing Drugs in Sports, Commentary 1 Stephen L. Brotherton, MD Physicians have an ethical obligation to warn athletes about the potential health problems associated with performance-enhancing drugs. Virtual Mentor. 2004;6(7):298-303. doi: 10.1001/virtualmentor.2004.6.7.ccas2-0407.
Viewpoint Nov 2005 Steroid Hysteria: Unpacking the Claims Norman Fost, MD, MPH A physician argues in favor of the use of performance-enhancing substances by adult participants in sports. Virtual Mentor. 2005;7(11):767-769. doi: 10.1001/virtualmentor.2005.7.11.oped2-0511.
Viewpoint Nov 2005 Medical Ethics and Performance-Enhancing Drugs Carlos R. Hamilton, MD A physician's role in controlling the abuse of performance-enhancing drugs includes educating patients about the harms associated with these drugs and encouraging them to adopt safe and appropriate training programs. Virtual Mentor. 2005;7(11):764-766. doi: 10.1001/virtualmentor.2005.7.11.oped1-0511.
Viewpoint Aug 2004 Cosmetic Neurology: For Physicians the Future is Now Anjan Chatterjee, MD Medications for brain enhancement raise many ethical concerns regarding the roles of personal autonomy and responsibility. Virtual Mentor. 2004;6(8):367-371. doi: 10.1001/virtualmentor.2004.6.8.oped1-0408.
In the Literature Aug 2004 Ethical Issues in the Application and Prescription of CNS Interventions Abraham P. Schwab, PhD A neuroscientist and a sociologist discuss the ethical concerns with common neurological medicines that are used to enhance or change behavior. Virtual Mentor. 2004;6(8):347-349. doi: 10.1001/virtualmentor.2004.6.8.jdsc1-0408.
Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 2 Lucy Godley, MD, PhD Physicians can help oncology patients decide whether to focus on aggressive chemotherapy or less aggressive comfort measures for end-of-life care. Virtual Mentor. 2004;6(11):479-481. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411.
In the Literature Nov 2004 Maintaining Integrity in Industry-Sponsored Research Alison Bickford Many ethical and legal issues arise when academic medical research is sponsored by pharmaceutical companies. Virtual Mentor. 2004;6(11):490-493. doi: 10.1001/virtualmentor.2004.6.11.jdsc2-0411.
Case and Commentary Nov 2004 Clinical Trials and End-of-Life Decision Making, Commentary 1 David S. Alberts, MD Physicians can help oncology patients decide whether to focus on aggressive chemotherapy or less aggressive comfort measures for end-of-life care. Virtual Mentor. 2004;6(11):477-479. doi: 10.1001/virtualmentor.2004.6.11.ccas1-0411.